GSK5458514
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
January 20, 2026
A study of GSK5458514 administered alone or in combination with other anticancer agents in patients with prostate cancer.
(ASCO-GU 2026)
- P1/2 | "Open sites are located in the United States, Japan, and Canada. Additional sites are planned to open in 2026 in Spain and France."
Clinical • Combination therapy • First-in-human • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor
February 18, 2026
223050: A Phase 1/2 First-Time-in-Human study of GSK5458514 administered alone or in combination with other anti-cancer agents in participants with mCRPC
(clinicaltrialsregister.eu)
- P1/2 | N=20 | Recruiting | Sponsor: Glaxosmithkline Research & Development Limited
New P1/2 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
June 30, 2025
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
(clinicaltrials.gov)
- P1/2 | N=82 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting
Enrollment open • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
May 27, 2025
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostrate Cancer
(clinicaltrials.gov)
- P1/2 | N=82 | Not yet recruiting | Sponsor: GlaxoSmithKline
New P1/2 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
1 to 4
Of
4
Go to page
1